HEMOGENYX PHARMACEUTICALS PLC

• ⚠

  Material uncertainty over going concern

  The Directors, having made due and careful enquiry, are of the opinion that the Company has or will have access to sufficient funding in order to execute its operations over the next 12 months, however a material uncertainty exists. The Directors have made an informed judgment, at the time of approving the financial statements, that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future, however this relies upon the Company raising additional capital. As a result, the Directors have adopted the going concern basis of accounting in the preparation of the annual financial statements.

1. HEMOGENYX PHARMACEUTICALS PLC 2017-10-04 → present
2. SILVER FALCON PLC 2014-11-25 → 2017-10-04
3. SILVER FALCON LIMITED 2013-02-13 → 2014-11-25

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

PKF Littlejohn LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Directors, having made due and careful enquiry, are of the opinion that the Company has or will have access to sufficient funding in order to execute its operations over the next 12 months, however a material uncertainty exists. The Directors have made an informed judgment, at the time of approving the financial statements, that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future, however this relies upon the Company raising additional capital. As a result, the Directors have adopted the going concern basis of accounting in the preparation of the annual financial statements.”

Group structure

1. HEMOGENYX PHARMACEUTICALS PLC · parent
   1. Hemogenyx UK Limited 100% · UK · Holding Company
   2. Hemogenyx Pharmaceuticals LLC 100% · USA · Biomedical sciences
   3. Immugenyx LLC 88.9% · USA · Biomedical sciences

Significant events

• “In January 2025 the Company raised £340,000 through the issue of 100,000 new ordinary shares at a price of 340p per share. One institutional investor was also granted 50,000 warrants exercisable at a price of 500p each for a period of 12 months from 1 March 2025.”
• “In February 2025 the Company raised £285,000 through the issue of convertible loan notes ("CLNs") and the loan note holders also received a one-for-one warrant, exercisable at a price of £4.00 per share for each share held upon the CLN conversion date. The CLNs converted into 95,000 ordinary shares on 13 March 2025.”
• “In February 2025, the Company terminated its Exclusive License Agreement with Cornell University.”
• “In March 2025 the Company raised £709,200 through the issue of 394,000 new ordinary shares at a price of 180p per share. The investor was also granted a one-for-two warrant, exercisable at a price of £3.50 per share for each share subscribed”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

14

last 12 months

Capital events

14

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -87.2%

  £1,247,601 → £159,265

• Net assets

  -69.3%

  £2,781,006 → £853,494

• Employees

  -5.9%

  17 → 16

• Operating profit

  +16.8%

  -£6,465,846 → -£5,377,087

• Profit before tax

  +16%

  -£6,696,493 → -£5,625,478

• Wages

  +0.7%

  £1,736,928 → £1,749,625

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers